MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers
MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers Data Featured in Poster at American Association for Cancer Research Annual Meeting 2021 Investor and Analyst Video Webcast Event on Tuesday, April 13, 2021 at 8:00 AM Eastern Time News provided by Share this article Share this article SAN DIEGO, April 10, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstrating that vorucic...
Source: prnewswire.com